Cherie Green

Cherie has been a long standing member and thought leader of the cytometry community for over 25 years focusing on hematopathology, cell therapy, and biotech biomarker laboratories. As a biomarker scientist, her professional focus lies in understanding cellular interactions in complex diseases and the development of novel therapies. She is passionate about development of innovative single assays and computational analysis solutions to advance life changing therapeutic development. During her tenure at Amgen, Genentech, and small cell therapy companies, she championed the design and use of biomarkers in clinical trial design for early and late stage drug development in infectious, autoimmune, and oncology diseases. She has served as the co-chair of Flow Cytometry Action Committee of the American Association of Pharmaceutical Scientists (AAPS) and has co-authored over 50 publications and patents on topics specific to drug development such as instrument and assay validation, sample stability, and receptor occupancy, and biomarkers.